Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Jung Ki | - |
dc.contributor.author | Lee, Han Sol | - |
dc.contributor.author | Lee, Young Ik | - |
dc.contributor.author | Lee, Sang Eun | - |
dc.contributor.author | Hong, Sung Kyu | - |
dc.date.accessioned | 2022-07-15T23:50:43Z | - |
dc.date.available | 2022-07-15T23:50:43Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2015-03 | - |
dc.identifier.issn | 1008-682X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157677 | - |
dc.description.abstract | We aimed to analyze the value of each criterion for clinically insignificant prostate cancer (PCa) in the selection of men for active surveillance (AS) of low-risk PCa. We identified 532 men who were treated with radical prostatectomy from 2006 to 2013 who met 4 or all 5 of the criteria for clinically insignificant PCa (clinical stage % T1, prostate specific antigen [PSA] density % 0.15, biopsy Gleason score % 6, number of positive biopsy cores % 2, and no core with > 50% involvement) and analyzed their pathologic and biochemical outcomes. Patients who met all 5 criteria for clinically insignificant PCa were designated as group A (n = 172), and those who met 4 of 5 criteria were designated as group B (n = 360). The association of each criterion with adverse pathologic features was assessed via logistic regression analyses. Comparison of group A and B and also logistic regression analyses showed that PSA density > 0.15 ng ml(1) and high (>= 7) biopsy Gleason score were associated with adverse pathologic features. Higher (> T1c) clinical stage was not associated with any adverse pathologic features. Although % 3 positive cores were not associated with any adverse pathology, >= 4 positive cores were associated with higher risk of extracapsular extension. Among potential candidates for AS, PSA density > 0.15 ng ml(1) and biopsy Gleason score > 6 pose significantly higher risks of harboring more aggressive disease. The eligibility criteria for AS may be expanded to include men with clinical stage T2 tumor and 3 positive cores. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MEDKNOW PUBLICATIONS & MEDIA PVT LTD | - |
dc.title | Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer. | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jo, Jung Ki | - |
dc.identifier.doi | 10.4103/1008-682X.142136 | - |
dc.identifier.scopusid | 2-s2.0-84924696845 | - |
dc.identifier.wosid | 000352069700018 | - |
dc.identifier.bibliographicCitation | ASIAN JOURNAL OF ANDROLOGY, v.17, no.2, pp.248 - 252 | - |
dc.relation.isPartOf | ASIAN JOURNAL OF ANDROLOGY | - |
dc.citation.title | ASIAN JOURNAL OF ANDROLOGY | - |
dc.citation.volume | 17 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 248 | - |
dc.citation.endPage | 252 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Andrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | JOHNS-HOPKINS | - |
dc.subject.keywordPlus | UPDATE | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | GUIDELINE | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordAuthor | prediction | - |
dc.subject.keywordAuthor | prostate | - |
dc.subject.keywordAuthor | prostatectomy | - |
dc.subject.keywordAuthor | prostatic neoplasms | - |
dc.subject.keywordAuthor | risk | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.